Why You Need An Ocular Disease Small Molecule Compound Library?

Ophthalmic drug discovery relies on a large number of targets, small molecules, and target-small molecule interactions in cheminformatics and bioinformatics for ocular diseases. Screening potential candidate compounds from a large number of small molecule compounds for ocular diseases can avoid blind activity screening of compounds. This can reduce the cost of the drug discovery process. A growing body of research has been used to discover potential drug targets for ocular diseases, including inhibitors of carbonic anhydrase (CA), vascular adhesion protein-1 (VAP-1), retinol-binding protein 4 (RBP4), and ocular puriner receptors etc. Using these emerging drug targets, constructing a high-quality library of ocular disease small molecule compounds can help to discover compounds with the greatest activity or inhibitory potential against a specific target, thereby expediting the development of ophthalmic products.

Fig. 1. Corneal collagen as an inflammatory mediator and therapeutic target in DED. (Baratta RO, et al., 2022)

Services Overview

Small molecule libraries are most commonly used in drug discovery programs to discover molecules with the greatest activity or inhibitory potential against a particular target. Ace Therapeutics' talented scientists in the fields of chemistry, proteology, and ophthalmology have constructed a simple and ready-to-use ocular disease small molecule compound library. For the design of screening libraries, we use emerging targets that are associated with multiple ophthalmic diseases covering dry eye, age-related macular degeneration (AMD), retinal diseases, diabetic macular edema, and many others.

We are proud that the ocular small molecule compound library we provide contains thousands of compounds, dozens of targets, and multiple ocular diseases. Each compound has information about it, such as its chemical structure, purity, quantity, and physicochemical properties. Based on our extensive knowledge of ocular disease small molecule compound libraries, we have the ability to re-create individual compounds and custom libraries to meet all your requirements.

Ace Therapeutics' Ocular Disease Small Molecule Compound Library

Ace Therapeutics has over 13,000 ocular small molecule screening compounds readily available in inventory currently, which can be custom selected and formatted according to your requirements. Whatever area of eye disease your research is targeting, our following ocular disease small molecule compound libraries are sufficient to support your research.

• Drug-Like Diversity Compound Library

The drug-like diversity compound library is our proudest compound. Our talented scientists have screened dozens of emerging targets for various eye diseases through long-term research, including tavilermide-induced mucin, vascular endothelial growth factor (VEGF), purinergic receptors, interleukin 4 (IL-4), retinol binding protein 4 (RBP4), and so on. On this basis, we use multiple high-throughput screening to obtain molecules that interact best with these dozens of targets, and their structures are also known to, constitute a primary compound library, and finally use a more focused library to further narrow the candidates in the library to only the most efficient.

• Natural Products Library

Based on ocular metabolomics and our research platform of live animal models of ocular diseases, the primary metabolites and secondary metabolites produced by different organisms with different ocular diseases are analyzed to form a natural product library.

• Bioactive Compound Library

Bioactive compounds refer to substances that can cause certain biological effects in the body, and are the main source of small-molecule drugs. We are able to design a biologically active compound library of over 7200 small molecule compounds with known activity and well-defined targets.

Features of Our Ocular Disease Small Molecule Compound Library

• Compounds: 13000 small molecule active compounds, dozens of targets, and multiple ocular diseases.
• ADMET: 1.6 million ADME and toxicity test data (29% absorption, 15% distribution, 25% metabolism, 4% excretion, 27% toxicity).
• Hot research fields: dry eye, retinal disease, glaucoma, cataracts, hereditary eye disease, etc.
• Targets: including corneal collagen, vascular endothelial growth factor (VEGF), purinergic receptors, interleukin 4 (IL-4), retinol binding protein 4 (RBP4), carbonic anhydrase (CA), vascular adhesion protein-1 (VAP-1), ocular puriner receptorss, and so on.

Ace Therapeutics' ocular disease small molecule compound library significantly reduces the cost of drug discovery, facilitates further experimentation, and accelerates the design process of ocular drugs for customers worldwide. Our talented scientists are always ready to explore unknown areas with you. If you are interested in our services or want to know more details, please feel free to contact us. We look forward to witnessing your success with you.

Reference

1. Baratta RO, Schlumpf E, Buono BJD, et al. Corneal collagen as a potential therapeutic target in dry eye disease. Surv Ophthalmol. 2022;67(1):60-67.

• Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Ligand-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Fragment-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Phenotype-Based Virtual Screening Services for Small Molecule Ophthalmic Drug Development
• Structure-Based Screening Services for Small Molecule Ophthalmic Drug Development
• High Throughput Screening Services for Small Molecule Ophthalmic Drug Development
• Computer-Aided Screening Services for Small Molecule Ophthalmic Drug Development

• * Name:
• Phone:
• * Email:
• * Services or Products of Interest:
• Project Description:
• * All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

  * Tick to confirm the Research Use Only (RUO) statement.

• Submit